<?xml version="1.0" encoding="UTF-8"?>
<p id="par0180">We must also reflect on safety in relation to the treatment of SARS-CoV-2. The pressing need to find an adequate treatment for COVID-19 has led to the use of drugs of unproven efficacy in this disease or based on the results of preclinical studies.
 <xref rid="bib0145" ref-type="bibr">
  <sup>29</sup>
 </xref> These drugs are not free of risk of potentially serious adverse effects, a risk that is currently accepted on account of the exceptional circumstances. The field of paediatrics is even more affected due to the scarcity of paediatric trials. Thus, paediatricians must also act with extreme caution and adhere to the current recommendations of experts and working groups of scientific societies.
</p>
